TY  - JOUR
A1  - Peveling-Oberhag, Jan Franz-Josef
A1  - Arcaini, Luca
A1  - Hansmann, Martin-Leo
A1  - Zeuzem, Stefan
T1  - Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management
T2  - Journal of hepatology
N2  - There is ample epidemiologic evidence for an association of chronic hepatitis C virus (HCV) infection with B-cell non-Hodgkin lymphoma (B-NHL). B-NHL subtypes most frequently associated with HCV are marginal zone lymphoma and diffuse large B-cell lymphoma. The most convincing evidence for a causal relationship between HCV infection and lymphoma development is the observation of B-NHL regression after HCV eradication by antiviral therapy (AVT). In fact, for indolent HCV-associated B-NHL, first-line AVT instead of standard immune-chemotherapy might be considered. Molecular mechanisms of HCV-NHL development are still poorly understood. Three general theories have emerged to understand the HCV-induced lymphomagenesis: (1) continuous external stimulation of lymphocyte receptors by viral antigens and consecutive proliferation; (2) HCV replication in B cells with oncogenic effect mediated by intracellular viral proteins; (3) permanent B-cell damage, e.g., mutation of tumor suppressor genes, caused by a transiently intracellular virus (“hit and run” theory). This review systematically summarizes the data on epidemiology, interventional studies, and molecular mechanisms of HCV-associated B-NHL.
KW  - Hepatitis C
KW  - Lymphoma
KW  - Antiviral therapy
KW  - B-cell
KW  - Non-Hodgkin lymphoma
Y1  - 2013
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/76872
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-768720
SN  - 0168-8278
VL  - 59
IS  - 1
SP  - 169
EP  - 177
PB  - Elsevier
CY  - Amsterdam
ER  -